3 results about "Keratoderma" patented technology

The application discloses application of Pemigatinib or a salt thereof in preparation of a medicine, and the compound is used for treating seborrheic keratosis, preferably seborrheic keratosis related to abnormal activation of a fibroblast growth factor receptor (FGFR) signal pathway, but is not limited to the above mechanism, and specifically, the medicine can inhibit or improve skin hyperplasia and hyperkeratosis lesions driven by FGFR3 gene activating mutation.

The present application relates to the field of dermatosis treatment and metabolic regulation, and discloses the use of a HAT modulator combined with an isoprene metabolite in the preparation of a drug for treating porokeratosis. The HAT modulator is preferably a p300 / CBP modulator, including an inhibitor, a degrader, a blocker, an antagonist or a combination thereof. The isoprene metabolite includes one or more of GGPP, FPP, IPP and DMAPP. The present application is based on the imbalance of metabolic flow of the mevalonate (MV) pathway and abnormal epigenetic regulation caused by MVD deficiency, establishes a metabolic-epigenetic coupling imbalance mechanism model, and proposes a combined intervention strategy for metabolic pathways and epigenetic regulation. The combined intervention can improve inflammatory response, abnormal keratinocyte differentiation and imbalance of the PI3K-AKT signal cascade. The combined intervention scheme provided by the present application has a clear mechanism and potential synergistic treatment advantages, and can be used for various types of PK and other inflammatory keratosis related to MV pathway abnormalities.

This invention relates to the application of hedera saponin A1 in the preparation of drugs for the prevention and / or treatment of seborrheic keratosis or its secondary lesions. Through molecular-level experiments, this invention verifies that hedera saponin A1 can directly bind to the AKT1 protein, inhibiting AKT1-induced upregulation of pro-apoptotic proteins, thereby initiating cell apoptosis. Compared with existing technologies, this invention is a non-invasive treatment, painless, non-invasive, and leaves no scars after healing. Furthermore, this invention has the dual efficacy of "treating seborrheic keratosis" and "chemopreventing malignant transformation." In addition, hedera saponin A1 has a significant killing effect on seborrheic keratosis lesion cells, exhibiting a killing effect on the epidermal layer of isolated seborrheic keratosis lesion tissue, but without inducing significant apoptosis in dermal cells.